---
title: "Moderna, Pfizer, and Novavax's stock prices surged sharply as the FDA approved COVID-19 vaccinations"
description: "Moderna, Pfizer, and Novavax's stock prices surged sharply as the FDA approved COVID-19 vaccinations for high-risk populations"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/254860291.md"
published_at: "2025-08-27T16:48:01.000Z"
---

# Moderna, Pfizer, and Novavax's stock prices surged sharply as the FDA approved COVID-19 vaccinations

> Moderna, Pfizer, and Novavax's stock prices surged sharply as the FDA approved COVID-19 vaccinations for high-risk populations

Moderna, Pfizer, and Novavax's stock prices surged sharply as the FDA approved COVID-19 vaccinations for high-risk populations

### Related Stocks

- [NVAX.US - Novavax](https://longbridge.com/en/quote/NVAX.US.md)
- [MRNA.US - Moderna](https://longbridge.com/en/quote/MRNA.US.md)
- [PFE.US - Pfizer](https://longbridge.com/en/quote/PFE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| FDA's Makary backs measles vaccinations as South Carolina cases rise | U.S. FDA Commissioner Martin Makary has urged Americans to vaccinate against measles amid a significant outbreak in Sout | [Link](https://longbridge.com/en/news/275950694.md) |
| Mexico enlists Moderna to boost mRNA supply for respiratory diseases | Mexico has entered a long-term agreement with Moderna to enhance its mRNA vaccine supply for respiratory diseases as par | [Link](https://longbridge.com/en/news/275641500.md) |
| Doctors bear the burden as ‘medical freedom’ fuels worst US measles outbreak in 30 years | The largest measles outbreak in the U.S. in over 30 years is occurring in South Carolina, with over 930 cases reported.  | [Link](https://longbridge.com/en/news/275888695.md) |
| Moderna Q4 revenue beats estimates on COVID vaccine sales, influenza vaccine filing accepted | Moderna's Q4 revenue reached $0.7 billion, surpassing analyst expectations, driven mainly by COVID vaccine sales. The co | [Link](https://longbridge.com/en/news/275897109.md) |
| 4-Sanofi ousts CEO Hudson after stalled turnaround at vaccine giant | Sanofi has ousted CEO Paul Hudson after a six-year tenure marked by a stalled turnaround and pressure on vaccine sales.  | [Link](https://longbridge.com/en/news/275748711.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.